Sacubitril/Valsartan

TargetMol
Product Code: TAR-T2318
Supplier: TargetMol
CodeSizePrice
TAR-T2318-2mg2mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-5mg5mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-10mg10mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-1mL1 mL * 10 mM (in DMSO)£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-25mg25mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-50mg50mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-100mg100mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2318-500mg500mg£466.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
LCZ696 is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for the treatment of hypertension and heart failure.
CAS:
936623-90-4
Formula:
C96H126N12Na6O21
Molecular Weight:
1922.066
Pathway:
Apoptosis; Endocrinology/Hormones; Metabolism
Purity:
0.9994
SMILES:
O.O.O.O.O.[NaH+].[NaH+].[NaH+].[NaH+].[NaH+].[NaH+].CCOC(=O)C(C)CC(Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC([O-])=O.CCOC(=O)C(C)CC(Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC([O-])=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[n-]n1)C(C(C)C)C([O-])=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[n-]n1)C(C(C)C)C([O-])=O
Target:
Apoptosis; RAAS; Neprilysin

References

1. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. PLoS One. 2016 May 12;11(5):e20154605. 2. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8. 3. Bai HY, et al. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage. Eur J Pharmacol. 2015 Sep 5;762:293-8.